Dr. Andrew E. Werchniak, MD

Dr. Werchniak practices at Seacoast Dermatology, a Forefront Dermatology Practice in Manitowoc, Wisconsin.

Dr. Werchniak's NPI, 1023075710, was assigned on April 27, 2006. Dr. Werchniak graduated from University of Virginia School of Medicine in 2002. Dr. Werchniak holds New Hampshire license 11723.

Dr. Werchniak's primary practice is Seacoast Dermatology, a Forefront Dermatology Practice, at 801 York St, Manitowoc, WI 54220 in Manitowoc County. The practice phone is (603) 431-5205.

Dr. Werchniak's primary practice is Seacoast Dermatology, a Forefront Dermatology Practice in Manitowoc, Wisconsin. The medical group on file is SeaCoast Dermatology (a Forefront Dermatology practice). Dmand AI also links Dr. Werchniak to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Werchniak practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Werchniak's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dmand AI has Dr. Werchniak's licenses on file in 2 states: New Hampshire and Massachusetts.

CMS data shows 7,988 Medicare services from Dr. Werchniak across 17 procedure codes in 2024, for 1,427 Medicare patients. Medicare paid $274,029 for them. Every service was in an office.

CMS counts 1,427 Medicare patients who saw Dr. Werchniak in 2024. The largest group is 65 to 74, with 648 patients. 75% of them have high cholesterol, and 66% have high blood pressure. 2% are also on Medicaid. Their average risk score is 0.87, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Werchniak's median patient age at 72, with 50% women.

In 2024, Dr. Werchniak wrote 965 Medicare Part D claims for 400 patients. 90% of them were for generic drugs. CMS names the drug for 825 of them, across 15 drugs with 11 or more claims each, at $239,092 in total drug cost. In 2023, CMS named 782 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Werchniak for performance year 2024, reported as part of a group. Dr. Werchniak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 1,931 procedures of removal of skin lesions by Dr. Werchniak, more than 98% of the clinicians it reports for that procedure.

Dmand AI links 14 papers to Dr. Werchniak, published from 2010 to 2021. 2015 was the busiest year, with 3. The most frequent topics are Skin Neoplasms, Health Knowledge, Attitudes, Practice and Health Behavior. Dr. Werchniak has published most often in JAMA Dermatol. Dr. Werchniak's most frequent co-authors are Gregory Aram Daniels, MD, PhD, Alan Loh Ho, MD, PhD and Karl D. Lewis, MD.

CMS Open Payments shows 5 general payments to Dr. Werchniak from 4 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 64% of the total. Abbvie Inc. paid the most, $35.

Dr. Werchniak graduated from University of Virginia School of Medicine in 2002.